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ABSTRACT
A broad range of naturally occurring antigenic variants of the influenza virus is caused by its rapid evolutionary variability. The 
survival of viable influenza virus variants occurs through natural selection. The treatment of influenza infection with modern 
antiviral drugs – neuraminidase (NA) inhibitors – leads to the occurrence of mutations in the NA gene, which thereby result in 
the emergence of virus resistance to these drugs. The goal of this study was to determine the selection pressure on the NA protein 
of influenza viruses isolated in Ukraine from 2009 to 2015. The main method for assessing the selection pressure on proteins is 
to quantify the ratio of substitution rates at nonsynonymous (dN) and synonymous (dS) sites. With the help of this method, we 
showed that only a few codons in the NA gene were under positive selection resulting in mutations at the following sites: for in-
fluenza A viruses of the A(H1N1)pdm09 subtype – site 40, for viruses of the A(H3N2) subtype – sites 93 and 402, for Influenza B vi-
ruses of the B/Yamagata lineage – sites 74, 99, and 268, and for the viruses of the B/Victoria lineage – sites 358, 288, and 455. These 
sites are not associated with the NA active site, transmembrane domain, or the antigenic sites of this protein. We concluded that 
NA inhibitors are not a significant factor in the process of selection of the influenza viruses in Ukraine because the sites associated 
with the resistance of influenza viruses to NA inhibitors were not affected by positive selection. This finding could be explained by 
the limited use of NA inhibitors for the treatment of influenza infections in Ukraine. 
INTRODUCTION
Annual seasonal circulations of influenza virus cause 
diseases in people that can account for significant mor-
tality – from 290,000 to 650,000 people – in the world 
population according to the estimates of the World 
Health Organization (WHO) [1, 2]. There are four known 
types of the influenza virus – A, B, C, and D, of which only 
type A and B viruses cause seasonal epidemics. Influenza 
A viruses in turn are divided into subtypes depending on 
the type of the main surface glycoproteins of the virus – 
hemagglutinin (HA) and neuraminidase (NA). Currently, 
18 subtypes of HA (HA1 - HA18) and 11 of NA (N1 - N11) 
are known. The two subtypes – A(H1N1) and A(H3N2) – 
are responsible for the seasonal influenza epidemics. For 
influenza B virus, two main lineages B/Yamagata and B/
Victoria are known. A broad variety of existing antigenic 
variants of the influenza virus is caused by its rapid evo-
lutionary variability [2, 3]. The high frequency of muta-
tions that occur in the genome of the influenza virus, 
represented by negative-sense single-stranded segment-
ed RNA, and the lack of proofreading activity of the viral 
RNA polymerase lead to the emergence of a large num-
ber of mutations that eventually cause the formation of 
new antigenic variants. This phenomenon is known as 
antigenic drift. The segmented structure of the influenza 
virus genome determines the ability to exchange frag-
ments between the strains of the same virus type, which 
leads to the emergence of new viruses and is called an-
tigenic shift. The survival of viable viral mutants is con-
trolled by natural selection.
The main licensed drugs that are currently used for 
the prevention and treatment of influenza A and influ-
enza B infections are the NA inhibitors – zanamivir, os-
eltamivir, laninamivir, and peramivir [4]. The mechanism 
of action of these drugs is based on blocking the function 
of viral NA and that leads to the limited spreading of the 
virus in the respiratory tract [5]. Peramivir and laninami-
vir inhibit NA activation for a much longer period of time 
than oseltamivir or zanamivir [6, 7]. However, the treat-
ment of patients with these drugs causes mutations in 
the NA gene and that leads to the formation and spread 
of drug resistant viruses. 
The analysis of the nucleotide sequences of HA and 
NA genes of the viruses isolated from patients in differ-
ent parts of the globe is widely used to predict the evo-
lutionary variability of the influenza virus as well as to 
predict the emergence of new epidemic strains using 
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bioinformatics methods, in particular by phylogenetic 
analysis [8]. In recent years, phylogenetic analysis has 
become one of the main components of epidemiological 
surveillance, which is used to determine the relation-
ship and evolution of influenza viruses [9]. Despite the 
fact that many research projects devoted to the study of 
the selection pressure on the genes of human influenza 
viruses have already been performed, the relationship 
between positively selected sites, antigenic variability 
of the virus, and sensitivity to NA inhibitors are still not 
fully understood [10-12].
The goal of the present study was to explore the ef-
fect of selection pressure on the NA gene of the influ-
enza viruses isolated in Ukraine in 2009-2015 as well as 
the identification of specific mutations in the NA gene of 
influenza virus isolates associated with resistance to NA 
inhibitors. 
The most common approach used to determine the 
selection pressure on proteins is the comparison of the 
nonsynonymous (dN) and synonymous (dS) substitu-
tion rates at the sites that are undergoing selection [13, 
14]. The dN/dS ratio quantifies the selection pressure 
by comparing the rate of these substitutions. If natural 
selection contributes to the fixing of the changes in the 
protein sequence, the value of the dN/dS ratio is greater 
than 1, while if natural selection inhibits changes in the 
protein, the value of this ratio is less than 1. If the value 
of the dN/dS ratio is close to 1, the selection pressure is 
absent. We applied this method to study the selection 
pressure on the NA gene of human influenza A viruses of 
A(H1N1)pdm09 and A(H3N2) subtypes as well as influ-
enza viruses of type B of both main lineages B/Yamagata 
and B/Victoria isolated in Ukraine in 2009-2015. The 
study of the effect of selection pressure on the HA gene 
was not a part of this project.
MATERIALS AND METHODS
Viruses
The influenza viruses isolated in epidemic seasons 2009-
2015 were used in this study. Samples were obtained from 
patients with influenza-like illness (ILI) and severe acute 
respiratory infections (SARI) in the form of nasal swabs, 
nasopharynx, or oropharynx. In addition, influenza vi-
rus isolates obtained from the sentinel centers in Kiev, 
Odessa, Dnipro, and Khmelnitsky were also included in 
this study. The diagnostics of SARI and ILI in patients 
was accomplished according to the WHO criteria [15].
Cell lines
The cell line of Madin-Darby canine kidney (MDCK), 
which was used in this study, was obtained from the 
Smorodintsev Research Institute of Influenza (St. Peters-
burg, Russian Federation). Influenza A(H3N2) viruses 
were isolated on a genetically modified MDCK-SIAT1 
cells obtained from the Centers for Disease Control and 
Prevention (CDC, Atlanta, USA) [16].
Real-time RT-PCR 
Isolation of RNA from the influenza viruses was carried 
out using the QIAamp® Viral RNA Mini Kit (QIAGEN, 
Germany) according to the manufacturer’s instructions. 
The reaction mixture for PCR was prepared according 
to the method for the detection of swine and seasonal 
A(H1N1)pdm09 influenza viruses as recommended by 
the CDC (Atlanta, USA) [17]. For the PCR, the Ambion 
AgPath-IDTM One-Step RT-PCR Kit and a set of primers 
and probes (Thermo Fisher Scientific, USA) were used. 
The reaction was carried out in a real-time PCR system 
Applied Biosystems real-time PCR 7500 (Thermo Fisher 
Scientific, USA).
Gene sequencing of influenza viruses
Gene sequencing of the isolated influenza A viruses of 
A(H3N2) and A(H1N1)pdm09 subtypes and type B influ-
enza viruses was carried out at the WHO Influenza Cen-
ter in London (National Institute for Medical Research, 
NIMR, London, UK) and at the CDC (Atlanta, USA) ac-
cording to the standard protocol [18]. All of the obtained 
nucleotide sequences were deposited to the international 
database – Global Initiative on Sharing Avian Influenza 
Data (GISAID, http://platform.gisaid.org/).
Phylogenetic analysis
The sequences of the NA genes obtained from influenza 
viruses isolated in the 2009-2015 epidemic seasons were 
used in this study. A total of 375  Ukrainian influenza 
virus isolates were examined. Of these, 142  sequences 
belong to influenza A type A(H1N1)pdm09 subtype, 
110  sequences belong to influenza A(H3N2) subtype, 
123 sequences – to type B influenza viruses (94 sequences 
to the B/Yamagata genetic lineage and 29 sequences to 
the B/Victoria genetic lineage). For the identification of 
mutations, the comparison of the obtained sequences 
was carried out using BLAST analysis (https://blast.ncbi.
nlm.nih.gov/Blast.cgi). For phylogenetic analysis, we se-
lected Ukrainian and European isolates obtained in the 
course of the study period as well as vaccine and refer-
ence strains. Multiple sequencing alignment was per-
formed using the ClustalW software [19]. Phylogenetic 
analysis was performed by means of the ML (maximum 
likelihood) method using the Tamura 92 (T92) model 
with an approximation of individual site frequencies by 
gamma distribution with bootstrap 1,000  replications. 
The construction of phylogenetic trees was carried out 
with MEGA6 software [20, 21]. The final trees were visu-
alized using FigTree 1.4.2 software [22].
The amino acid substitutions leading to resistance 
to NA inhibitors were identified: E119I (V/D), Q136K, 
D151E/V I222L, R224K, E276D, R292K, N294S, R371K – 
for influenza A viruses of A(H3N2) subtype; I117V, 
E119G/V, Q136K, Y155H, D198G, I222K/R/V, S246N/G, 
H274Y, N294S – for viruses of A(H1N1)pdm09 subtype; 
E119A (G, V, A/D), R152K, D198E (N/Y), I222T (V/I), 
H274Y, R292K, N294S, R371K, G402S – for type B influ-
enza viruses. Numbering was carried out according to N2 
[23].
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Study of selection pressure 
The study of the NA gene sequences of influenza viruses 
was carried out using the Datamonkey server [24, 25] and 
the following methods: SLAC (single-likelihood ances-
tor), FEL (fixed-effects likelihood), IFEL (internal branch 
fixed-effects likelihood), included in the software pack-
age HyPhy of the Datamonkey server. Furthermore, the 
method FUBAR (fast unconstrained Bayesian approxima-
tion) and MEME (mixed-effects model of evolution) were 
used. The ratio dN/dS was determined using HyPhy.
RESULTS
Influenza A(H1N1)pdm09 viruses 
One site (40) that is under positive selection pressure 
was detected in NA protein of the influenza A(H1N1)
pdm09 viruses: the L40V mutation was found in four 
isolates from the 2012-2013 season, and L40I mutation 
in viruses circulating in the 2013-2014 and 2014-2015 
seasons (Table 1, Fig. 1). A modest effect of positive se-
lection pressure on pandemic influenza viruses was also 
recorded by other authors, although they revealed muta-
tions at different sites [12].
Phylogenetic analysis of influenza viruses of the 
A(H1N1)pdm09 subtype revealed a high level of identity, 
99%. All Ukrainian influenza viruses were similar to the 
A/California/07/2009 virus that was used for the vaccine 
strain preparation.
Although Ukrainian isolates of the A(H1N1)pdm09 
subtype acquired unique mutations, the majority of sub-
stitutions were located in the same sites as in the isolates 
from the neighboring countries [26–31]. For example, all 
the Ukrainian isolates of the 2014-2015 epidemic season 
contained the typical I117M substitution and were simi-
lar to the strains from European countries such as Italy, 
Latvia, Poland, Slovakia, France, Estonia, etc. Similar vi-
ruses were isolated in New Zealand [32]. These results 
suggest that mutations in the NA gene did not lead to 
significant changes of the NA antigenic properties of the 
influenza viruses of this subtype.
Influenza A(H3N2) viruses
Two sites that are under positive selection pressure – 93 
and 402 – were detected in influenza viruses of A(H3N2) 
subtype using at least one of the following methods – 
FEL, IFEL, and FUBAR (Table 1).
The Ukrainian isolate A/Ukraine/175/2011 acquired 
mutations D93E and D402N and was similar to the iso-
lates from Belarus and Estonia as well as to the Ukrainian 
isolates from the next epidemic season. D93E mutation 
was observed only in one isolate A/Ukraine/5381/2012 
in the next season. However, in the 2012-2013 season, a 
group of viruses with D93G mutation was isolated again. 
Therefore, the D93E mutation appeared in the popula-
tion of Ukrainian influenza viruses in the 2010-2011 sea-
son, and in the next season (2011-2012) amino acid 93G 
was observed at this position, and the D93G mutation 
was still present in the population of Ukrainian viruses 
in the 2012-2013 season (Fig. 2). Belanov et al. consider 
the D93G mutation as one of the evolutionary markers of 
influenza viruses of A(H3N2) subtype [33]. Starting from 
the 2012-2013 season, the virus used for the preparation 
of the vaccine strain also contained this mutation.
The analysis of the sequences of viruses from accessible 
databases (Influenza Virus Resource (IVR) and GISAID) 
revealed substitution T267K that is considered to be an 
evolutionary marker, which was observed in some Ukrai-
nian isolates from the 2014-2015 season.
Phylogenetic analysis of influenza A(H3N2) viruses 
revealed a high level of genetic identity of these viruses, 
98.3%. 
It is noteworthy that in the 2013-2014 season, the two 
viruses A/Ukraine/710/2013 and A/Ukraine/728/2013, 
which only differed by one substitution G401D in the NA 
protein, were isolated from the same person within a few 
days. The amino acid at this position is the part of the NA 
antigenic site [34].
Table 1. The results of the assessment of selection pressure on the NA of influenza viruses isolated in Ukraine
Type/subtype of 
the virus
dN/dS Sites under the selection pressure
positive negative
Site Mutation Season, years Total number of sites Sites, studied by 4 methods *
A(H1N1)pdm 0.261 40 L40V 2012-2013 27 2 sites: 395, 439
L40І 2013-2015
A(H3N2) 0.205 93 D93E 2010-2011 58 10 sites: 106, 107, 128, 182, 296, 
306, 364, 427, 432, 449D93G 2011-2012
402 N402D 2010-2011





В/Victoria 0.292 358 А358К 2011-2012 17 1 site: 371
288 Е288Q 2010-2011
455 L455І
*Sites were studied by SLAC, FEL, IFEL, and FUBAR methods
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Fig. 1. Phylogenetic tree of NA gene of A(H1N1)pdm09 viruses.
Viruses isolated in Ukraine are marked in blue (viruses of the 2010-2011 season are highlighted in yellow, viruses isolated in 2013-2014 are 
highlighted in light green); the vaccine strain is marked in red; the reference strains are marked in green.
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Fig. 2. Phylogenetic tree of NA gene of A(H3N2) viruses.
Viruses isolated in Ukraine are marked in blue (viruses of the 2010-2011 season are highlighted in yellow, viruses of 2013-2014 are high-
lighted in light green); the vaccine strains are marked in red; the reference strains are marked in green.
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Type B influenza viruses of the B/Yamagata lineage
The study of influenza B viruses of the B/Yamagata ge-
netic lineage showed the presence of three sites – 74, 99, 
and 268 – under the positive selection pressure (Table 1). 
Substitutions T268K, S99I, and L74P were observed only 
in the isolates of 2014-2015 season. At the same time, the 
isolates with L74P mutation form a separate group on a 
phylogenetic tree (Fig. 3).
Phylogenetic analysis of the NA gene of influenza 
B/Yamagata viruses during the studied period showed 
high genetic identity, 97.5%. Influenza viruses isolated 
in Ukraine during the studied period were similar to the 
viruses recommended for the preparation of vaccine 
strains in the same epidemic season.
Some of the found substitutions theoretically can af-
fect the conformation of the NA protein. Some Ukrainian 
isolates contained substitutions at potential glycosyl-
ation sites (A465T, R65H) or NA stem region (R65H). In 
addition, substitutions at the T125K and V71L (loop-120) 
were found. The amino acid substitutions T125K, E148G 
(loop-150), and D235N (helix-190) were found in some 
viruses isolated in the 2013-2014 season [26]. According 
to the data of the Influenza Center in London [27], the 
influenza viruses isolated in this season contained indi-
vidual substitutions that were atypical for the Ukrainian 
isolates, namely: T46I, A55T, G70R, E77A, I262T, R295H, 
A358T, and K382R.
Type B influenza viruses of the B/Victoria lineage
For influenza viruses of type B of the genetic lineage B/
Victoria, the following sites under the positive selection 
pressure were found: 358, 288, and 455 (IFEL, MEME) 
(Table 1). In some cases, only the single mutations 
E288Q and L455I were found in Ukrainian isolates cir-
culated during the 2010-2011 epidemic season (Fig.  4). 
However, the A358K mutation, which appeared in viruses 
circulated in the 2011-2012 season, was observed in all 
the isolates of the B/Victoria lineage. This result shows 
that the above-mentioned substitution has been fixed in 
the influenza virus population as a result of positive se-
lection pressure. A phylogenetic comparison of the NA 
genes of the B/Victoria lineage isolates revealed a high 
level of genetic identity of 98.4%. 
DISCUSSION
The gradual accumulation of mutations in the gene leads 
to a change in the structure of the encoded protein, which 
in turn can lead to a change in the biological properties 
of the virus, such as the rate of virus spreading, the se-
verity of the disease caused by the virus, contagiousness, 
sensitivity to drugs, etc. [2]. The study of mechanisms of 
molecular adaptation of influenza viruses is one of the 
fundamental goals of evolutionary biology. Nonsynony-
mous mutations are fixed in the population more often 
than synonymous ones. This is usually observed when 
new mutations provide certain advantages for the pro-
tein (virus); then, they have a greater chance of fixation. 
This phenomenon is regularly observed in the course 
of the evolution of RNA-containing viruses leading to 
changes of surface antigens HA and NA in the case of in-
fluenza virus.
The present paper presents the results of the first 
study of the selection pressure effect on the variability 
of the NA protein of human influenza viruses and the 
emergence of resistance to NA inhibitors conducted in 
Ukraine. The analysis results of the NA sequences of vi-
ruses isolated in Ukraine in the period from 2009 to 2015 
are as follows: the dN/dS ratio was 0.261 for NA of the 
influenza A viruses of A(H1N1)pdm09 subtype, 0.205 for 
NA of viruses of A(H3N2) subtype, 0.226 for NA of type 
B viruses of B/Yamagata lineage, and 0.292 for NA of 
B/Victoria lineage viruses. The obtained data show that 
the number of synonymous substitutions prevails over 
the number of nonsynonymous ones for each site of NA 
protein. This means that for most of the substitutions in 
the NA gene, the selection pressure is absent. 
The values of the dN/dS ratio determined in this study 
for the NA of the influenza viruses of different types and 
subtypes are in good agreement with the data reported 
by other authors. Therefore, Mostafa et al. reported a dN/
dS ratio equal to 0.22 for the NA of the influenza A(H3N2) 
subtype viruses isolated in Germany in 2015 [35], and a 
similar value for this ratio was reported by Li et al. who 
studied 1,397  viruses of the A(H1N1)pdm09 subtype in 
China [12]. In the course of analysis of 98 sequences of 
NA of the influenza B type viruses of B/Yamagata lineage 
by Horthongkham et al. in Bangkok [36], the dN/dS ratio 
was found to be 0.20. 
We found that only some sites in the NA turned out to 
be under positive selection pressure: site 40 for viruses 
of A(H1N1)pdm09 subtype, sites 93 and 402 for influ-
enza A(H3N2) viruses, sites 74, 99, and 268 for influenza 
B viruses of the B/Yamagata lineage, and sites 358, 288, 
and 455 for the viruses of the B/Victoria lineage. These 
sites do not belong to the active center, transmembrane 
domain, or antigenic sites of NA. However, as a result of 
the selection pressure, mutations at these positions were 
fixed in the influenza virus population and these virus-
es often formed a separate branch on the phylogenetic 
tree. These results were proved by analyzing a number 
of selected sites by all four methods (SLAC, IFEL, FEL, 
and FUBAR). In one of the isolates of the B/Yamagata 
lineage – B/Odessa /389/2015 – the L83P mutation was 
detected. Since this mutation was not found in the influ-
enza virus population in the 2017-2018 season, it was not 
a fixed mutation.  
The treatment of influenza with NA inhibitors can 
create selective pressure on the emergence of virus re-
sistance to these drugs, which can in turn affect the ge-
netic diversity of the viral population. The emergence of 
the viral resistance to the antiviral drugs is an important 
problem of public health care. However, in the course of 
our study, no positive selection pressure was found on 
the sites associated with resistance to NA inhibitors. 
Therefore, in Ukraine, NA inhibitors are not a significant 
factor in the process of selection of the influenza viruses. 
Apparently, this is due to the fact that NA inhibitors are 
not widely used for the treatment of influenza infections 
in Ukraine. However, these studies should be continued.
Selection pressure on the NA gene
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Fig. 3. Phylogenetic tree of the NA gene of influenza viruses of B/Yamagata lineage.
Viruses isolated in Ukraine are marked in blue; the vaccine strains are marked in red; the reference strains are marked in green.
 Volume 6   Number 1     2019 67 mir-journal.org 
Selection pressure on the NA gene
Fig. 4. Phylogenetic tree of the NA gene of influenza viruses of B/Victoria lineage.
Viruses isolated in Ukraine are marked in blue; the vaccine strain is marked in red. The strains of 2009-2010 are highlighted in blue.
Selection pressure on the NA gene
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